Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease

References

• Afroz N, Gutzwiller FS, Mackay AJ, Naujoks C, Patalano F, Kostikas K. Patient-Reported Outcomes (PROs) in COPD clinical trials: trends and gaps. Int J Chron Obstruct Pulmon Dis. 2020;15:1789–1800. doi:10.2147/COPD.S235845
   PubMed Web of Science ®Google Scholar
• Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–1266. doi:10.1056/NEJMra1900500
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (2021 Report). Global initiative for chronic obstructive lung disease; 2021. Available from: https://goldcopd.org/2021-gold-reports/. Accessed February 4, 2022.
   Google Scholar
• Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007;62(7):595–601. doi:10.1136/thx.2006.064428
   PubMed Web of Science ®Google Scholar
• James BD, Jones AV, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: is exercise the answer? Chron Respir Dis. 2018;15(2):173–181. doi:10.1177/1479972317736294
   PubMed Web of Science ®Google Scholar
• Zewari S, Hadi L, van den Elshout F, Dekhuijzen R, Heijdra Y, Vos P. Obesity in COPD: comorbidities with practical consequences? Copd. 2018;15(5):464–471. doi:10.1080/15412555.2018.1509951
   PubMedGoogle Scholar
• McDonald VM, Wood LG, Holland AE, Gibson PG. Obesity in COPD: to treat or not to treat? Expert Rev Respir Med. 2017;11(2):81–83. doi:10.1080/17476348.2017.1267570
   PubMed Web of Science ®Google Scholar
• Santana AN, Souza R, Martins AP, Macedo F, Rascovski A, Salge JM. The effect of massive weight loss on pulmonary function of morbid obese patients. Respir Med. 2006;100(6):1100–1104. doi:10.1016/j.rmed.2005.09.021
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21. doi:10.1111/dom.13129
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736–743. doi:10.2967/jnumed.106.038679
   PubMed Web of Science ®Google Scholar
• Brock C, Hansen CS, Karmisholt J, et al. Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol. 2019;85(11):2512–2523. doi:10.1111/bcp.14063
   PubMed Web of Science ®Google Scholar
• Liu X, Huang J, Li J, Mao Q, He J. Effects of liraglutide combined with insulin on oxidative stress and serum MCP-1 and NF-kB levels in Type 2 diabetes. J Coll Physicians Surg Pak. 2019;29(3):218–221. doi:10.29271/jcpsp.2019.03.218
   PubMed Web of Science ®Google Scholar
• Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503–4511. doi:10.1210/en.2013-1666
   PubMed Web of Science ®Google Scholar
• Wei YF, Tseng WK, Huang CK, Tai CM, Hsuan CF, Wu HD. Surgically induced weight loss, including reduction in waist circumference, is associated with improved pulmonary function in obese patients. Surg Obes Relat Dis. 2011;7(5):599–604. doi:10.1016/j.soard.2011.04.221
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Linderholm A, Haczku A, Kenyon N. Glucagon-like peptide 1: a potential anti-inflammatory pathway in obesity-related asthma. Pharmacol Ther. 2017;180:139–143. doi:10.1016/j.pharmthera.2017.06.012
   PubMed Web of Science ®Google Scholar
• Huang J, Yi H, Zhao C, et al. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:3191–3202. doi:10.2147/COPD.S175145
   PubMed Web of Science ®Google Scholar
• Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in patients with Type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021;203(7):831–840. doi:10.1164/rccm.202004-0993OC
   PubMed Web of Science ®Google Scholar
• Carolina LC, Ciudin A, Sánchez E, et al. Liraglutide improves forced vital capacity in individuals with type 2 diabetes: data from the randomized cross-over LIRALUNG Study. Diabetes. 2021;4:540.
   Google Scholar
• Frazer DG, Reynolds JS, Jackson MC. Determining when enhanced pause (Penh) is sensitive to changes in specific airway resistance. J Toxicol Environ Health A. 2011;74(5):287–295. doi:10.1080/15287394.2010.514235
   PubMed Web of Science ®Google Scholar
• Lundblad LK, Irvin CG, Hantos Z, Sly P, Mitzner W, Bates JH. Penh is not a measure of airway resistance Eur Respir J. 2007;30(4):805. doi:10.1183/09031936.00091307
   PubMed Web of Science ®Google Scholar
• Xu WH. Repetitive measurements of enhanced pause (Penh). Respir Physiol Neurobiol. 2015;206:41–44. doi:10.1016/j.resp.2014.11.006
   PubMed Web of Science ®Google Scholar
• Bikov A, Lange P, Anderson JA, et al. FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1135–1142. doi:10.2147/COPD.S242809
   PubMed Web of Science ®Google Scholar
• Ben Saad H, Préfaut C, Tabka Z, Zbidi A, Hayot M. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther. 2008;21(5):767–773. doi:10.1016/j.pupt.2008.04.005
   PubMed Web of Science ®Google Scholar
• Casanova C, Gonzalez-Dávila E, Martínez-Gonzalez C, et al. Natural course of the diffusing capacity of the lungs for carbon monoxide in COPD: importance of sex. Chest. 2021;160(2):481–490. doi:10.1016/j.chest.2021.03.069
   PubMed Web of Science ®Google Scholar
• Vigna M, Aiello M, Bertorelli G, Crisafulli E, Chetta A. Flow and volume response to bronchodilator in patients with COPD. Acta Biomed. 2018;89(3):332–336. doi:10.23750/abm.v89i3.5631
   PubMedGoogle Scholar
• Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026
   PubMed Web of Science ®Google Scholar
• Wu TD, Ejike CO, Wise RA, McCormack MC, Brigham EP. Investigation of the obesity paradox in chronic obstructive pulmonary disease, according to smoking status, in the United States. Am J Epidemiol. 2019;188(11):1977–1983. doi:10.1093/aje/kwz185
   PubMed Web of Science ®Google Scholar